CL2008000422A1 - El compuesto acido 4-[4-(2-adamantilcarbamoil)-5-terbutilpirazol-1-il]-benzoico; composicion farmaceutica; su uso como inhibidor de 11bhsd1, util en el tratamiento de la diabetes tipo 2 y la obesidad. - Google Patents

El compuesto acido 4-[4-(2-adamantilcarbamoil)-5-terbutilpirazol-1-il]-benzoico; composicion farmaceutica; su uso como inhibidor de 11bhsd1, util en el tratamiento de la diabetes tipo 2 y la obesidad.

Info

Publication number
CL2008000422A1
CL2008000422A1 CL2008000422A CL2008000422A CL2008000422A1 CL 2008000422 A1 CL2008000422 A1 CL 2008000422A1 CL 2008000422 A CL2008000422 A CL 2008000422A CL 2008000422 A CL2008000422 A CL 2008000422A CL 2008000422 A1 CL2008000422 A1 CL 2008000422A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
11bhsd1
adamantylcarbamoyl
butylpyrazol
obesity
Prior art date
Application number
CL2008000422A
Other languages
English (en)
Inventor
James Stewart Scott
Paul Robert Owen Whittamore
Martin John Packer
Andrew Stocker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39438215&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000422(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2008000422A1 publication Critical patent/CL2008000422A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de pirazol sustituido; proceso de preparación; composición farmacéutica; y uso para producir un efecto inhibitorio de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1 en enfermedades, tales como, síndrome metabólico.
CL2008000422A 2007-02-12 2008-02-08 El compuesto acido 4-[4-(2-adamantilcarbamoil)-5-terbutilpirazol-1-il]-benzoico; composicion farmaceutica; su uso como inhibidor de 11bhsd1, util en el tratamiento de la diabetes tipo 2 y la obesidad. CL2008000422A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88933607P 2007-02-12 2007-02-12
US98573507P 2007-11-06 2007-11-06

Publications (1)

Publication Number Publication Date
CL2008000422A1 true CL2008000422A1 (es) 2009-01-02

Family

ID=39438215

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008000422A CL2008000422A1 (es) 2007-02-12 2008-02-08 El compuesto acido 4-[4-(2-adamantilcarbamoil)-5-terbutilpirazol-1-il]-benzoico; composicion farmaceutica; su uso como inhibidor de 11bhsd1, util en el tratamiento de la diabetes tipo 2 y la obesidad.

Country Status (23)

Country Link
US (2) US7816391B2 (es)
EP (2) EP2292228A1 (es)
JP (1) JP2010518063A (es)
KR (1) KR20090108726A (es)
CN (1) CN102503891A (es)
AR (1) AR065300A1 (es)
AU (1) AU2008215976B2 (es)
BR (1) BRPI0808450A2 (es)
CA (1) CA2676154A1 (es)
CL (1) CL2008000422A1 (es)
CO (1) CO6220949A2 (es)
EC (1) ECSP099571A (es)
IL (1) IL200047A0 (es)
MX (1) MX2009008506A (es)
NZ (1) NZ578568A (es)
PE (2) PE20090649A1 (es)
RU (2) RU2462456C2 (es)
SA (1) SA08290055B1 (es)
SG (1) SG177892A1 (es)
TW (1) TW200836719A (es)
UY (1) UY30912A1 (es)
WO (1) WO2008099145A1 (es)
ZA (1) ZA201000838B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006316087B2 (en) 2005-11-21 2011-03-10 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-beta-hydroxysteroid dehydrogenase type I
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
BRPI0811191A2 (pt) 2007-05-18 2014-10-29 Shionogi & Co Derivado heterocíclico contendo nitrogênio tendo atividade inibitória para 11beta-hidroxiesteroide deidrogenase tipo 1
AU2008277783B2 (en) 2007-07-17 2012-09-20 F. Hoffmann-La Roche Ag Inhibitors of 11beta-hydroxysteroid dehydrogenase
WO2009098501A1 (en) * 2008-02-04 2009-08-13 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
CN102066335A (zh) * 2008-04-22 2011-05-18 阿斯利康(瑞典)有限公司 取代的嘧啶-5-甲酰胺281
JP2012516327A (ja) * 2009-01-30 2012-07-19 アストラゼネカ アクチボラグ カルボキシ含有ピラゾールアミド化合物を製造するための新規な方法
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
GB201004301D0 (en) * 2010-03-15 2010-04-28 Syngenta Participations Ag Process
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5605104B2 (ja) * 2010-09-10 2014-10-15 セントラル硝子株式会社 ピラゾール化合物の製造方法
DE112012002522T5 (de) 2011-06-22 2014-03-13 Central Glass Co., Ltd. Verfahren zur Herstellung einer Pyrazol-Verbindung
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2015129094A (ja) * 2012-04-16 2015-07-16 大日本住友製薬株式会社 アリールアミノピラゾール誘導体
WO2019042267A1 (zh) * 2017-08-28 2019-03-07 中国医学科学院药物研究所 吡咯-2-甲酰胺类化合物及其制备方法和用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (es) * 1978-02-21 1981-03-27 Delalande Sa
US4816391A (en) * 1984-02-29 1989-03-28 Syntex (U.S.A.) Inc. Amine stabilized aminoglycoside formulations
CA1307786C (en) 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
PT1219609E (pt) 1999-09-16 2007-06-19 Tanabe Seiyaku Co ''compostos cíclicos aromático azotados de seis membros''
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
DK1383731T3 (da) 2000-10-20 2009-12-07 Biocryst Pharm Inc Biarylforbindelser som serinproteaseinhibitorer
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2005528395A (ja) 2002-04-05 2005-09-22 ザ ユニバーシティ オブ エディンバラ 組成物
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
CN101712657A (zh) 2003-02-26 2010-05-26 万有制药株式会社 杂芳基氨基甲酰基苯衍生物
DE602004027171D1 (de) * 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
CN1832741A (zh) 2003-08-07 2006-09-13 默克公司 作为11－β－羟甾类脱氢酶－1抑制剂的吡唑甲酰胺类
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
WO2005060963A1 (en) 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
WO2005108359A1 (en) 2004-05-06 2005-11-17 Pfizer Inc. Novel compounds of proline and morpholine derivatives
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
AU2005256442B2 (en) 2004-06-28 2009-02-12 F. Hoffmann-La Roche Ag Pyrimidine derivatives as 11beta-HSD1 inhibitors
CA2585735A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Novel compounds of substituted and unsubstituted adamantyl amides
EP1809290A2 (en) 2004-11-03 2007-07-25 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
BRPI0606256A2 (pt) 2005-01-05 2009-06-09 Abbott Lab inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos
CN101155783B (zh) 2005-04-05 2012-01-04 霍夫曼-拉罗奇有限公司 吡唑类化合物
CA2602787C (en) 2005-04-06 2013-12-24 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
EP1891069A1 (en) 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200716576A (en) 2005-06-07 2007-05-01 Shionogi & Co Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2006132436A1 (ja) * 2005-06-08 2006-12-14 Japan Tobacco Inc. 複素環化合物
CA2610903A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-yl)-sulfonamide derivatives
AU2006268406C1 (en) 2005-07-09 2011-02-24 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
EP1915367A1 (en) 2005-08-09 2008-04-30 AstraZeneca AB Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
CA2627813A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
AU2006316087B2 (en) * 2005-11-21 2011-03-10 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-beta-hydroxysteroid dehydrogenase type I
CA2635814A1 (en) 2006-01-31 2007-08-09 Incyte Corporation Amido compounds and their use as pharmaceuticals
HUE026011T2 (en) * 2006-03-22 2016-05-30 Hoffmann La Roche Pyrazoles as 11-beta-HSD-1
CA2648074A1 (en) 2006-04-07 2007-10-18 High Point Pharmaceuticals, Llc 11.beta.-hydroxysteroid dehydrogenase type 1 active compounds
WO2007125049A1 (en) 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Use of cbx cannabinoid receptor modulators as potassium channel modulators
US20100022589A1 (en) * 2006-07-27 2010-01-28 Mccoull William Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
BRPI0811191A2 (pt) 2007-05-18 2014-10-29 Shionogi & Co Derivado heterocíclico contendo nitrogênio tendo atividade inibitória para 11beta-hidroxiesteroide deidrogenase tipo 1
AU2008277783B2 (en) 2007-07-17 2012-09-20 F. Hoffmann-La Roche Ag Inhibitors of 11beta-hydroxysteroid dehydrogenase
CN101909621A (zh) * 2007-11-06 2010-12-08 阿斯利康(瑞典)有限公司 4-[4-(2-金刚烷基氨基甲酰基)-5-叔丁基-吡唑-1-基]苯甲酸-465
WO2009098501A1 (en) 2008-02-04 2009-08-13 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
CN102066335A (zh) * 2008-04-22 2011-05-18 阿斯利康(瑞典)有限公司 取代的嘧啶-5-甲酰胺281
JP2012516327A (ja) 2009-01-30 2012-07-19 アストラゼネカ アクチボラグ カルボキシ含有ピラゾールアミド化合物を製造するための新規な方法
TW201118085A (en) * 2009-10-20 2011-06-01 Astrazeneca Ab Adamantyl iminocarbonyl-substituted pyrimidines as inhibitors of 11-β-HSD1

Also Published As

Publication number Publication date
EP2292228A1 (en) 2011-03-09
BRPI0808450A2 (pt) 2014-08-12
CN102503891A (zh) 2012-06-20
UY30912A1 (es) 2008-09-30
AU2008215976B2 (en) 2011-11-24
SA08290055B1 (ar) 2012-09-26
RU2462456C2 (ru) 2012-09-27
NZ578568A (en) 2012-01-12
AU2008215976A1 (en) 2008-08-21
US20110224273A1 (en) 2011-09-15
CO6220949A2 (es) 2010-11-19
US7816391B2 (en) 2010-10-19
ECSP099571A (es) 2009-09-29
PE20090649A1 (es) 2009-06-26
AR065300A1 (es) 2009-05-27
US20090221663A1 (en) 2009-09-03
KR20090108726A (ko) 2009-10-16
CA2676154A1 (en) 2008-08-21
IL200047A0 (en) 2010-04-15
ZA201000838B (en) 2010-10-27
TW200836719A (en) 2008-09-16
MX2009008506A (es) 2009-10-12
RU2009133259A (ru) 2011-03-20
US8344016B2 (en) 2013-01-01
WO2008099145A1 (en) 2008-08-21
PE20120355A1 (es) 2012-05-17
RU2012125372A (ru) 2013-12-27
JP2010518063A (ja) 2010-05-27
SG177892A1 (en) 2012-02-28
EP2124937A1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
CL2008000422A1 (es) El compuesto acido 4-[4-(2-adamantilcarbamoil)-5-terbutilpirazol-1-il]-benzoico; composicion farmaceutica; su uso como inhibidor de 11bhsd1, util en el tratamiento de la diabetes tipo 2 y la obesidad.
BRPI0606256A2 (pt) inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos
EA200870474A1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
CL2007001972A1 (es) Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos.
CL2009001203A1 (es) Compuestos derivados de indazol y pirazol sustituidos; composicion farmaceutica de dichos compuestos; kit farmaceutico; y su uso como activadores de la glucoquinasa para tratar enfermedades metabolicas tales como hiperglicemia, diabetes, dislipidemias, obesidad, sindrome metabolico x y enfermedades cardiovasculares.
WO2010046445A3 (en) Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
ATE471311T1 (de) Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
WO2011056985A3 (en) Substituted heterocyclic compounds
MY148079A (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
ECSP088839A (es) Derivados de lactamas de ciclohexilpirazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
WO2009100872A8 (en) Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
CL2012001043A1 (es) Compuestos derivados de hexahidroindenopiridina y/o octahidrobenzoquinolina, inhibidores de 11ß-hidroxiesteroide deshidrogenasa 1 (hsd 1); composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos para la preparacion de medicamentos para el tratamiento de trastornos metabolicos.
ECSP088849A (es) Pirrolidinonas sustituidas de pieridinil como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
CR20110485A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
PH12015501116A1 (en) New indanyloxydihydrobenzofuranylacetic acids
WO2009063061A3 (en) Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
EA201100503A1 (ru) Глюкозидные производные и их применения
NO20090064L (no) Pyrasoler som glucokinase aktivatorer
UY31986A (es) Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MX2010008583A (es) Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
CL2012003681A1 (es) Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes.